Cure8 research brief
Fecal calprotectin is a noninvasive stool biomarker used to detect intestinal inflammation and to help distinguish IBD from noninflammatory conditions.
This study reports strong diagnostic accuracy and a correlation between calprotectin levels and UC severity, which is relevant for monitoring disease activity and guiding treatment decisions.
Patients with ulcerative colitis, clinicians who follow IBD patients, and researchers interested in biomarker development for IBD.
A recent case-control study from Iraq measured fecal calprotectin by ELISA in 63 patients with clinicopathologically confirmed ulcerative colitis and 87 healthy controls. The paper reports much higher mean fecal calprotectin in UC patients versus controls and stepwise higher concentrations with increasing Mayo severity (mild, moderate, severe).
The authors calculated a diagnostic cut-off of 85.5 μg/g with sensitivity ~90.5% and specificity ~87.4% for distinguishing UC from controls. They conclude fecal calprotectin is a useful noninvasive biomarker that correlates with disease severity and inflammatory burden.
If you use fecal calprotectin in care, this study adds single-center, case-control data supporting its diagnostic and severity-assessment value, but it does not replace clinical judgment or guideline-based thresholds.
Single-center case-control design and use of a specific commercial ELISA limit generalizability; cut-off values and assay results can differ across labs and populations. This report is from an abstract/full-text of the journal article and should be considered alongside larger studies and clinical guidelines.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Noninvasive blood biomarkers that track IBD activity could reduce reliance on repeat endoscopy. If validated, serum galectin‑3 might complement fecal calprotectin and CRP to help identify active disease.
The study describes a new urine-based fluorescent biosensor that detected inflamed intestinal sites and tracked treatment response earlier and more sensitively than fecal calprotectin in a mouse model of IBD, which could...
CMV reactivation can worsen outcomes in active UC and influence treatment choices; clinicians and patients may benefit from additional, easy-to-measure markers that flag higher risk of tissue CMV and prompt targeted...
